发明授权
US07622464B2 Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases
有权
用于治疗炎性疾病的吗啉基 - 脲衍生物
- 专利标题： Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases
- 专利标题（中）： 用于治疗炎性疾病的吗啉基 - 脲衍生物
-
申请号： US10509162申请日： 2003-03-27
-
公开(公告)号： US07622464B2公开(公告)日： 2009-11-24
- 发明人: Rachael Ann Ancliff , Caroline Mary Cook , Colin David Eldred , Paul Martin Gore , Lee Andrew Harrison , Martin Alistair Hayes , Simon Teanby Hodgson , Duncan Bruce Judd , Suzanne Elaine Keeling , Xiao Qing Lewell , Gail Mills , Graeme Michael Robertson , Stephen Swanson , Andrew John Walker , Mark Wilkinson
- 申请人： Rachael Ann Ancliff , Caroline Mary Cook , Colin David Eldred , Paul Martin Gore , Lee Andrew Harrison , Martin Alistair Hayes , Simon Teanby Hodgson , Duncan Bruce Judd , Suzanne Elaine Keeling , Xiao Qing Lewell , Gail Mills , Graeme Michael Robertson , Stephen Swanson , Andrew John Walker , Mark Wilkinson
- 申请人地址： GB Greenford, Middlesex
- 专利权人： Glaxo Group Limited
- 当前专利权人： Glaxo Group Limited
- 当前专利权人地址： GB Greenford, Middlesex
- 代理商 James P. Rick
- 优先权： GB0207434.2 20020328; GB0301608.6 20030124
- 国际申请： PCT/EP03/03335 WO 20030327
- 国际公布： WO03/082861 WO 20031009
- 主分类号： A61K31/535
- IPC分类号： A61K31/535 ; C07D413/14 ; C07D413/12
摘要：
Compounds of formula (I): wherein: R1 represents substituted or unsubstituted heteroaryl; Y represents —(CRnaRnb)n—; Rna and Rnb are each independently hydrogen or C1-6alkyl; n is an integer from 0 to 5; R2 represents unsubstituted or substituted aryl or unsubstituted or substituted heteroaryl; R3 and R4 each independently represent hydrogen or C1-6-alkyl; R7 represents hydrogen or C1-6alkyl; R8 represents hydrogen or C1-6alkyl; and salts and solvates thereof; are CCR3 antagonists and are thus indicated to be useful in therapy.
公开/授权文献
- US20060063765A1 Novel compounds 公开/授权日：2006-03-23
信息查询
